GlycoMimetics, Inc. (GLYC)
NASDAQ$0.2596
Market Cap
$16.75M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
308 of 925
Rank in Industry
176 of 528
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
GLYC Insider Trading Activity
GLYC Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $83,159 | 3 | 25 |
Sells | $488,749 | 9 | 75 |
Related Transactions
| Rock Edwin | Chief Medical Officer | 2 | $78,825 | 0 | $0 | $78,825 |
| Hahn Brian M. | SVP Finance, CFO | 1 | $4,335 | 0 | $0 | $4,335 |
| Invus Public Equities, L.P. | 10 percent owner | 0 | $0 | 9 | $488,749 | $-488,749 |
About GlycoMimetics, Inc.
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect …
Insider Activity of GlycoMimetics, Inc.
Over the last 12 months, insiders at GlycoMimetics, Inc. have bought $83,159 and sold $488,749 worth of GlycoMimetics, Inc. stock.
On average, over the past 5 years, insiders at GlycoMimetics, Inc. have bought $2.17M and sold $2.74M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Rock Edwin (Chief Medical Officer) — $78,825. Hahn Brian M. (SVP Finance, CFO) — $4,335.
The last purchase of 115,000 shares for transaction amount of $30,717 was made by Rock Edwin (Chief Medical Officer) on 2024‑06‑21.
List of Insider Buy and Sell Transactions, GlycoMimetics, Inc.
| 2024-08-08 | Sale | Invus Public Equities, L.P. | 10 percent owner | 260,873 0.4135% | $0.19 | $50,009 | +34.59% | |
| 2024-08-07 | Sale | Invus Public Equities, L.P. | 10 percent owner | 61,488 0.0996% | $0.18 | $11,197 | +44.72% | |
| 2024-08-06 | Sale | Invus Public Equities, L.P. | 10 percent owner | 55,732 0.0882% | $0.18 | $10,188 | +40.79% | |
| 2024-08-05 | Sale | Invus Public Equities, L.P. | 10 percent owner | 164,523 0.2612% | $0.19 | $30,996 | +36.99% | |
| 2024-08-02 | Sale | Invus Public Equities, L.P. | 10 percent owner | 286,200 0.4383% | $0.20 | $57,354 | +24.24% | |
| 2024-08-01 | Sale | Invus Public Equities, L.P. | 10 percent owner | 63,564 0.0987% | $0.22 | $13,743 | +16.76% | |
| 2024-07-30 | Sale | Invus Public Equities, L.P. | 10 percent owner | 756,835 1.1897% | $0.22 | $167,185 | +15.18% | |
| 2024-07-29 | Sale | Invus Public Equities, L.P. | 10 percent owner | 363,949 0.5697% | $0.24 | $85,637 | +7.63% | |
| 2024-07-26 | Sale | Invus Public Equities, L.P. | 10 percent owner | 258,335 0.4016% | $0.24 | $62,440 | +4.02% | |
| 2024-06-21 | Rock Edwin | Chief Medical Officer | 115,000 0.1787% | $0.27 | $30,717 | +0.47% | ||
| 2024-06-20 | Rock Edwin | Chief Medical Officer | 190,000 0.2799% | $0.25 | $48,108 | +3.16% | ||
| 2024-06-18 | Hahn Brian M. | SVP Finance, CFO | 17,500 0.0252% | $0.25 | $4,335 | +6.32% | ||
| 2023-09-22 | Rock Edwin | Chief Medical Officer | 30,403 0.0463% | $1.38 | $41,956 | -0.71% | ||
| 2023-09-21 | Rock Edwin | Chief Medical Officer | 35,000 0.0544% | $1.38 | $48,300 | +2.17% | ||
| 2023-05-17 | Sale | Hahn Brian M. | SVP Finance, CFO | 3,700 0.0059% | $1.95 | $7,215 | -15.69% | |
| 2023-05-10 | JUNIUS DANIEL M | director | 30,000 0.0441% | $1.56 | $46,800 | -1.14% | ||
| 2023-05-08 | Johnson Bruce S | SVP & Chief Commercial Officer | 13,500 0.0237% | $1.57 | $21,195 | +18.24% | ||
| 2023-02-24 | Invus Public Equities, L.P. | 10 percent owner | 100,000 0.1667% | $1.70 | $170,000 | -5.03% | ||
| 2023-02-23 | Invus Public Equities, L.P. | 10 percent owner | 200,000 0.3399% | $1.75 | $350,760 | -5.85% | ||
| 2023-02-22 | Invus Public Equities, L.P. | 10 percent owner | 150,000 0.2504% | $1.79 | $268,995 | -9.55% |
Total: 84
*Gray background shows transactions not older than one year
Insider Historical Profitability
2.47%
| Invus Public Equities, L.P. | 10 percent owner | 6317565 9.7926% | $1.64M | 8 | 9 | <0.0001% |
| Rock Edwin | Chief Medical Officer | 680403 1.0547% | $176,632.62 | 7 | 0 | <0.0001% |
| Hahn Brian M. | SVP Finance, CFO | 70643 0.1095% | $18,338.92 | 2 | 3 | +31.85% |
| BVF PARTNERS L P/IL | 10 percent owner | 4980812 7.7205% | $1.29M | 3 | 0 | <0.0001% |
| BARRIS PETER J | 10 percent owner | 4702791 7.2896% | $1.22M | 1 | 2 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$992,222,850 | 90 | -12.52% | $19.11M | |
$8,900,811 | 57 | -24.79% | $14.9M | |
$6,204,522 | 45 | 1.91% | $18.93M | |
GlycoMimetics, Inc. (GLYC) | $85,897,100 | 36 | 2.47% | $16.75M |
$217,684 | 34 | 1.61% | $17.84M |
GLYC Institutional Investors: Active Positions
| Increased Positions | 22 | +47.83% | 16M | +91.35% |
| Decreased Positions | 16 | -34.78% | 4M | -20.74% |
| New Positions | 16 | New | 16M | New |
| Sold Out Positions | 11 | Sold Out | 3M | Sold Out |
| Total Postitions | 52 | +13.04% | 30M | +70.62% |
GLYC Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Bvf Inc/Il | $2,596.00 | 14.68% | 9.54M | 0 | 0% | 2024-12-31 |
| Logos Global Management Lp | $1,469.00 | 8.31% | 5.4M | +5M | New | 2024-12-31 |
| Adage Capital Partners Gp, L.L.C. | $1,385.00 | 7.83% | 5.09M | +5M | New | 2024-12-31 |
| Vr Adviser, Llc | $816.00 | 4.62% | 3M | +3M | New | 2024-12-31 |
| Vanguard Group Inc | $726.00 | 4.11% | 2.67M | 0 | 0% | 2024-12-31 |
| Wellington Management Group Llp | $384.00 | 2.17% | 1.41M | +1M | New | 2024-12-31 |
| Blackrock, Inc. | $198.00 | 1.12% | 728,637 | +779 | +0.11% | 2024-12-31 |
| Geode Capital Management, Llc | $142.00 | 0.8% | 521,223 | 0 | 0% | 2024-12-31 |
| Jefferies Financial Group Inc. | $115.00 | 0.65% | 423,777 | +423,777 | New | 2024-12-31 |
| Adar1 Capital Management, Llc | $90.00 | 0.51% | 331,827 | +286,127 | +626.1% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
No data is available at this moment.
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.